Please ensure Javascript is enabled for purposes of website accessibility

What We Know About the Idaho Shooting That Killed 2 Firefighters

2 hours ago

Shaver Lake and Reedley 4th of July Shows Are Wednesday. Who Else Is Celebrating?

3 hours ago

Elon Musk Says Senate Bill Would Destroy Jobs and Harm US

3 hours ago

Israel Strikes Pound Gaza, Killing 60, Ahead of US Talks on Ceasefire

4 hours ago

Trump’s Administration Finds Harvard Violated Students’ Civil Rights, WSJ Reports

5 hours ago

How Did the Supreme Court Rule? Here’s a Look at the Big Cases

2 days ago

US Consumer Spending Falls as Trump Tariff’s Muddle Economy

3 days ago

Motorcycle Collides With Tractor in Fatal Fresno County Collision

3 days ago
AstraZeneca: US Data Shows Vaccine Effective for All Adults
gvw_ap_news
By Associated Press
Published 4 years ago on
March 22, 2021

Share

LONDON — AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among all adults in a long-anticipated U.S. study, raising hopes that the findings could help rebuild public confidence in the beleaguered shot in other countries and moving a step closer to clearance for American use.

AstraZeneca said the vaccine was 79% effective overall at preventing symptomatic cases of COVID-19 — including in older people — and that none of the study volunteers who were vaccinated were hospitalized or developed severe disease. The company also said its experts did not identify any safety concerns related to the vaccine, including finding no increased risk of rare blood clots identified in Europe.

Will Seek US Approval Soon

The findings bolster AstraZeneca’s prior research in Britain and other countries, and add to real-world evidence that the shots are offering good protection as they’re used more widely. But confidence in the vaccine has been repeatedly hit because of concerns about how data was reported from some previous trials, confusion over its efficacy in older adults and a recent scare over clotting.

AstraZeneca said it will seek clearance in the United States “in the coming weeks,” putting it on track to arrive just as the country is projected to have a big boost in supplies of three other vaccines — from Pfizer, Moderna and Johnson & Johnson — that already are in use.

AstraZeneca’s interim results are based on 141 COVID-19 cases in the 30,000-person trial, but officials declined to tell reporters during a news conference Monday how many were in study volunteers who received the vaccine and how many in those who got dummy shots. Two-thirds of the volunteers received vaccine.

“These findings reconfirm previous results observed,” said Ann Falsey, of the University of Rochester School of Medicine, who helped lead the trial. “It’s exciting to see similar efficacy results in people over 65 for the first time.”

30 Million Doses Ready

A Food and Drug Administration advisory committee will publicly debate the evidence behind the shots before the agency decides whether to allow emergency use. Ruud Dobber, an AstraZeneca executive vice president, said that if the FDA OK’s the vaccine, the company will deliver 30 million doses immediately — and another 20 million within the first month.

The AstraZeneca shot, which has been authorized in more than 70 countries, is a pillar of a U.N.-backed project known as COVAX that aims to get COVID-19 vaccines to poorer countries, and it has also become a key tool in European countries’ efforts to boost their sluggish vaccine rollouts. That important role in the global strategy to stamp out the pandemic make doubts about the shot especially worrying.

Stephen Evans, of the London School of Hygiene & Tropical Medicine, said the new data could help to allay concerns about the vaccine.

“The benefits of these results will mainly be for the rest of the world where confidence in the AZ (AstraZeneca) vaccine has been eroded, largely by political and media comment,” he said.

Dr. Paul Hunter, a professor of medicine at the University of East Anglia, said the results were reassuring but that more details were needed to back up AstraZeneca’s claim that the vaccine was completely effective at preventing severe disease and hospitalization.

”It would be good to know how many severe cases occurred in the control group and so what the confidence intervals are for this 100% figure,” said Hunter, who was not connected to the study. “But this should add confidence that the vaccine is doing what it is most needed for.”

Scientists had hoped the U.S. study would clear up some of the confusion about just how well the shots really work, particularly in older people. Previous research suggested the vaccine was effective in younger populations, but there was no solid data proving its efficacy in those over 65, often those most vulnerable to COVID-19.

Problems with European Rollout

Britain first authorized the vaccine based on partial results from testing in the United Kingdom, Brazil and South Africa that suggested the shots were about 70% effective. But those results were clouded by a manufacturing mistake that led some participants to get just a half dose in their first shot — an error the researchers didn’t immediately acknowledge.

Then came more questions, about how well the vaccine protected older adults and how long to wait before the second dose. Some European countries including Germany, France and Belgium initially withheld the shot from older adults and only reversed their decisions after new data suggested it was offering seniors protection.

AstraZeneca’s vaccine development was rocky in the U.S., too. Last fall, the FDA suspended the company’s study for an unusual six weeks, as frustrated regulators sought information about some neurologic complaints reported in Britain; ultimately, there was no evidence the vaccine was to blame.

Last week, more than a dozen countries, mostly in Europe, temporarily suspended their use of the AstraZeneca shot after reports it was linked to rare blood clots — even as international health agencies insisted the benefits of the vaccine outweighed the risks. On Thursday, the European Medicines Agency concluded after an investigation that the vaccine did not raise the overall risk of blood clots, but could not rule out that it was connected to two very rare types of clots. It recommended adding a warning about these cases to the vaccine’s leaflet.

It’s not unheard of for such rare problems to crop up as vaccines are rolled out since trials typically look at tens of thousands of people, and some issues are only seen once the shot is used in millions of people.

France, Germany, Italy and other countries subsequently resumed their use of the shot on Friday, with senior politicians rolling up their sleeves to show the vaccine was safe.

The AstraZeneca shot is what scientists call a “viral vector” vaccine. The shots are made with a harmless virus, a cold virus that normally infects chimpanzees. It acts like a Trojan horse to carry the coronavirus’s spike protein’s genetic material into the body that in turn produces some harmless protein. That primes the immune system to fight if the real virus comes along.

Two other companies, Johnson & Johnson and China’s CanSino Biologics, make COVID-19 vaccines using the same technology but using different cold viruses.

RELATED TOPICS:

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Apple Loses Bid to Dismiss US Smartphone Monopoly Case

DON'T MISS

US Supreme Court Tosses Rulings That Favored Transgender People

DON'T MISS

Trump Administration Sues Los Angeles Over Immigration Enforcement

DON'T MISS

Catholic Bishops Try to Rally Opposition to Trump’s Immigration Agenda

DON'T MISS

US Revokes Visas for Bob Vylan After Music Duo’s Glastonbury Chants

DON'T MISS

Israel Acknowledges Palestinian Civilians Harmed at Gaza Aid Sites, Says ‘Lessons Learned’

DON'T MISS

What We Know About the Idaho Shooting That Killed 2 Firefighters

DON'T MISS

Immigration Raids Leave Crops Unharvested, California Farms at Risk

DON'T MISS

Valley Crime Stoppers’ Most Wanted Person of the Day: Anthony Michael Caldwell

DON'T MISS

Shaver Lake and Reedley 4th of July Shows Are Wednesday. Who Else Is Celebrating?

UP NEXT

US Supreme Court Lets Parents Take Kids Out of Classes With LGBT Storybooks

UP NEXT

Bill Moyers, Broadcaster and LBJ’s White House Press Secretary, Dies at 91

UP NEXT

Tesla Executive, Elon Musk Confidant Leaves EV Maker, Bloomberg News Reports

UP NEXT

How a Birthday Boat Ride on Lake Tahoe Turned Tragic

UP NEXT

Cuomo Concedes to Mamdani in New York City Democratic Mayoral Contest

UP NEXT

Mamdani Holds Lead Over Cuomo in Democratic Primary for NYC Mayor

UP NEXT

Clovis Man Sentenced to 8 Years in Federal Prison in Deadly Fentanyl Case

UP NEXT

Victims Identified as Death Toll Climbs to 8 in Lake Tahoe Boating Tragedy

UP NEXT

Florida to Build ‘Alligator Alcatraz’ Detention Center for Migrants in Everglades

UP NEXT

Americans Worry Conflict With Iran Could Escalate, Reuters/Ipsos Poll Finds

Catholic Bishops Try to Rally Opposition to Trump’s Immigration Agenda

2 hours ago

US Revokes Visas for Bob Vylan After Music Duo’s Glastonbury Chants

2 hours ago

Israel Acknowledges Palestinian Civilians Harmed at Gaza Aid Sites, Says ‘Lessons Learned’

2 hours ago

What We Know About the Idaho Shooting That Killed 2 Firefighters

2 hours ago

Immigration Raids Leave Crops Unharvested, California Farms at Risk

3 hours ago

Valley Crime Stoppers’ Most Wanted Person of the Day: Anthony Michael Caldwell

3 hours ago

Shaver Lake and Reedley 4th of July Shows Are Wednesday. Who Else Is Celebrating?

3 hours ago

Elon Musk Says Senate Bill Would Destroy Jobs and Harm US

3 hours ago

Fresno Police Arrest DUI Suspect With Loaded Gun During Traffic Stop

3 hours ago

Israel Faces Genocide Accusations Amid Gaza Food Aid Killings

3 hours ago

Apple Loses Bid to Dismiss US Smartphone Monopoly Case

Apple must face the U.S. Department of Justice’s lawsuit accusing the iPhone maker of unlawfully dominating the U.S. smartphone market...

15 minutes ago

People walk by the Apple store on Fifth Avenue in New York City, U.S., May 1, 2025. (Reuters File)
15 minutes ago

Apple Loses Bid to Dismiss US Smartphone Monopoly Case

People participate in an event to raise Bucks County's Pride Flag to kick off Pride Month in Doylestown, Pennsylvania, U.S., June 1, 2023. (Reuters File)
58 minutes ago

US Supreme Court Tosses Rulings That Favored Transgender People

A U.S. Justice Department logo or seal showing Justice Department headquarters, known as "Main Justice," is seen behind the podium in the Department's headquarters briefing room before a news conference with the Attorney General in Washington, January 24, 2023. (Reuters File)
1 hour ago

Trump Administration Sues Los Angeles Over Immigration Enforcement

Cardinal Robert McElroy, archbishop of Washington
2 hours ago

Catholic Bishops Try to Rally Opposition to Trump’s Immigration Agenda

Bob Vylan hold the Best Alternative Music Act Award during the 25th MOBO Awards in London, Britain November 30, 2022. (Reuters File)
2 hours ago

US Revokes Visas for Bob Vylan After Music Duo’s Glastonbury Chants

Women embrace, while mourning loved ones, during the funeral of Palestinians killed by Israeli fire yesterday, as they sought aid in northern Gaza, according to Gaza's health ministry, at Al-Shifa Hospital, in Gaza City, June 19, 2025. (Reuters File)
2 hours ago

Israel Acknowledges Palestinian Civilians Harmed at Gaza Aid Sites, Says ‘Lessons Learned’

Idaho Firefighters Shot and Killed
2 hours ago

What We Know About the Idaho Shooting That Killed 2 Firefighters

Immigrant workers harvest crops during the weekend, as labor shortages risk leaving fields unpicked, in Oxnard, California, U.S., June 22, 2025. REUTERS/Pilar Olivares
3 hours ago

Immigration Raids Leave Crops Unharvested, California Farms at Risk

Help continue the work that gets you the news that matters most.

Search

Send this to a friend